Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Silica is a proven and highly effective anti-caking agent that has been used for decades
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Subscribe To Our Newsletter & Stay Updated